

A Review –Role R-DNA Technology in Human Being

Vasundhara Kakade¹, Vishal Galave², Archana Salunkhe³, Dr. Kishor Otari⁴, Priyanka Nangare Amruta Menkundale⁵, Tejal Galave⁶, Monali Jagtap⁷

^{1,2,3,4,5} Navasahyadri Institute of Pharmacy, Nasarapur, Pune

⁶Shardabai Pawar Mahila Mahavidyalaya, Shardanagar, Baramati

⁷PDEA'S Waghire College, Saswad

Abstract- Human being is significantly affected by three factors: insufficiency of food, physical condition problems, and environmental issues. Food and strength are basic human requirements alongside a fresh and safe environment. In the olden times century, the recombinant DNA technology was presently an mind that advantageous quality can be enhanced in the income bodies by domineering the terms of intention genes. Recombinant DNA technology comprise altering genetic substance exterior an organism to obtain better and required character in living organisms or as their products. The arrival of recombinant DNA technology revolutionize the improvement in biology and led to a sequence of remarkable change.

Index terms- R-DNA, gene, therapy, genetic material


INTRODUCTION

Recombinant DNA technology is playing a vital role in improving health conditions by developing new vaccines and pharmaceuticals. The treatment strategies are also improved by developing diagnostic kits, monitoring devices, and new therapeutic approaches. Production of artificial human insulin and erythropoietin by hereditarily adapted bacteria. The beginning of recombinant DNA knowledge revolutionize the development in biology and led to a series of dramatic change. The pharmaceutical goods synthesized through recombinant DNA technology, completely changed the human life in such a way that the U.S. Food and Drug Administration (FDA) permitted more recombinant drugs in 1997.

HISTORY: In, 1972 David Jackson, Robert Symons and Paul Berg successfully generated R-DNA molecules. In 1970 Howard Temin and Davin Baltimore in parallel naked the enzyme Reverse transcriptase since retroviruses. Later on this enzyme was used to construct a DNA called complementary DNA (cDNA) from any mRNA. In 1973 for the first

time S. Cohen and H. Boyer residential a recombinant plasmid (pSC101) which behind with as vector replicated well within a bacterial congregation. In, 1975, Edwin M. Southern developed a method for detection of specific DNA fragments for isolation of a gene from complex mixture of DNA. This method is known as the Southern blotting technique.

STEPS INVOLVING IN R-DNA TECHNOLOGY



1-separation of Genetic Material

- The initial step in r-DNA technology is to separate the preferred DNA in its unadulterated form i.e. free from other macromolecules.

- while DNA exist inside the cell membrane next to through extra macromolecules such as RNA, polysaccharides, proteins, lipids, it should be divided and purified which involve enzymes such as lysozymes, cellulose, Ribo-nuclease, proteases etc.
- Additional macromolecules are detachable with other enzymes or treatment. In time, the accumulation of ethanol causes the DNA to spontaneous out as superior mechanism. This is then wind out to give purify DNA.

2-Restriction Enzyme incorporation

- Restriction enzymes act as molecular cutters that cut DNA at definite locations. These reactions are called ‘restriction enzyme incorporation’.
- They entail the incubation of the purify DNA with the select restriction enzyme, at condition mainly constructive for that definite enzyme.
- The technique ‘Agarose Gel Electrophoresis’ reveal the progress of the restriction enzyme digestion.
- This technique involves running out the DNA on an agarose gel. On the application of current, the negatively exciting DNA movements to the positive electrode and is divided out based on size. This allows extrication and cutting out the digested DNA fragments.
- The vector DNA is also process using the same method.

3. Amplification Using PCR

- Polymerase Chain Reaction or PCR is a method of make numerous copy of a DNA progression via the enzyme – DNA polymerase in vitro.
- It help to amplify a particular copy or a not many copy of DNA into thousands to millions of copies.
- PCR reactions are run on ‘thermal cyclers’ using the following components:
 - 1 Template – DNA to be augmented
 - 2 Primers – small, chemically synthesize oligonucleotides that are corresponding to a region of the DNA.
 - 3 Enzyme – DNA polymerase
 - 4 Nucleotides – desirable to extend the primers by the enzyme.

- The cut fragments of DNA can be amplified with PCR and then ligated with the scratch vector.

4. Ligation of DNA Molecules



- The purify DNA and the vector of notice are cut with the same restriction enzyme.
- This give us the engrave piece of DNA and the engrave vector, that is now open.
- The method of joining these two pieces together using the enzyme ‘DNA ligase’ is ‘ligation’.
- The resulting DNA molecule is a crossbreed of two DNA molecules – the importance molecule and the vector. In the terminology of inheritance this intermixing of different DNA strands is called recombination.
- Hence, this new hybrid DNA molecule is also called a recombinant DNA fragment and the technology is referred to as the recombinant DNA technology.

5. Inclusion of Recombinant DNA In to Host

- In this step, the recombinant DNA is introduce into a receiver host cell typically, a bacterial cell. This progression is ‘Transformation’.
- Bacterial cells do not recognize distant DNA easily. Therefore, they are treat to make them ‘competent’ to accept new DNA. The process used may be thermal shock, Ca⁺⁺ ion treatment, electroporation etc.

6. Isolation of Recombinant Cells

- The transformation process generates a mix population of transformed and non-trans- formed host cells.
- The collection process involves filter the transformed host cells only.
- For isolation of recombinant cell from non-recombinant cell, marker gene of plasmid vector is engaged.
- For examples, PBR322 plasmid vector contain diverse indication genetic material (Ampicillin unwilling gene and Tetracycline resistant gene). When pst1 RE is used it knock out Ampicillin unwilling gene from the plasmid, so that the recombinant cell befall susceptible to Ampicillin.
- TOOLS rDNA TECHNOLOGY



phosphatase treatment to prevent vector circulation during DNA insert integration. Cohesive ends are converted to blunt ends by removing protruding nucleotides using S1 nuclease, which degrades single-stranded protruding DNA. The new DNA sequence is created by inserting a synthetic DNA fragment called

- 1 Restriction enzyme-cuts both strands of dsDNA within a symmetrical recognition site resulting in blunt or sticky ends.
- 2 Reverse transcriptase-synthesizes a DNA copy of an RNA molecule
- 3 DNA polymerase-fills gaps in duplexes by stepwise addition of nucleotides to 3' ends.
- 4 DNA ligase- It joins two DNA molecules or fragments
- 5 Alkaline phosphatase- removes terminal phosphates from either the 5' or 3' end (or both)

INSERTION OF TARGET DNA INTO VECTOR

Insertion of a DNA fragment into a vector can be performed when both the target gene and vector are cut with the same restriction enzyme to produce identical cohesive ends. The 3' ends of a DNA strand always carry a free hydroxyl group, while their 5' ends contain a phosphate group. The ends of a DNA strand produced by a restriction enzyme have to be modified for gene cloning. The 5' end phosphate group of vector DNA is removed by alkaline

APPLICATIONS OF RECOMBINANT DNA TECHNOLOGY

Health and Diseases. Recombinant DNA technology has a wide spectrum of applications in treating diseases and improving health conditions. The following sections describe the important breakthroughs of recombinant DNA technology

- 1 Gene Therapy: Gene therapy is a superior method with therapeutic prospects in health services. The first unhealed report in the field of gene analysis to delay a genetic disease provided a more sheltered direction toward curing the deadly hereditary disease. (M. Cauzzana 2000) genetic material transmitted to a small number of cells at anatomically distinct sites is an embattled scheme that has the potential to confer therapeutic gain. Many different cancers as well as-
 - 1 Lung
 - 2 Gynaecological skin,
 - 3 -Urological
 - 4 Neurological, and gastrointestinal tumours,
 - 5 -Haematological malignancies (M.Gott, 2006) (Stein 2010)

- 2 Investigation of the Drug Metabolism: Complex classification of drug metabolizing enzymes involved in the drug metabolism is essential to be checked up for the appropriate efficiency and belongings of drugs. Recombinant DNA come near have in recent times supply its role through Heterosexual appearance where the enzyme's hereditary information is expressed in vitro or in vivo, through the transfer of genetic material. (A. Rostami-Hodjegan 2007) (J. K. Nicholson, E. Holmes 2012)
- 3 Development of Vaccines and Recombinant Hormones: Moderately predictable vaccines have lower effectiveness and specificity than recombinant vaccine.
- 4 Environment: Genetic engineering has extensive purpose in solve the environmental issue. The discharge of genetically engineered microbes, for example, *Pseudomonas fluorescence* strain designated HK44, for bioremediation purpose it the field was primary practiced by University of Tennessee and Oak Ridge National Laboratory by operational in collaboration. (S Ripp 2000) (G.saylair 1999)
- 5 Agriculture:In agriculture growth of genetically adapted crop with a function to progress both comply and struggle to plant pests or herbicides seem to have gained a degree of public acceptance and is already practice in a commercial framework in a number of countries. The genetically adapted tomato CGN-89564-2 was the first commercially developed, hereditarily engineered crop invention to be decided a license for human consumption. This was developed in 1994 to express the trait of deferred softening of tomato flesh as a realistic means to reduce post-harvest crop losses. Ironically given its brand name of 'FlavrSavr', this futile in the bazaar due not to public uneasiness over eating a genetically altered food per se but to an apparent lack of taste. all the same, the introduction of a hereditarily adapted fruit lined the way for use of GMOs in food and today genetic change is widespread. In the US, 88% of corn and 93% of soybeans are genetically altered and much of this finds its way unlabeled into process foods.

- [1] <https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/recombinant-dna-technology>.
- [2] <https://microbenotes.com/recombinant-dna-technology-steps-applications-and-limitations/>
- [3] Verma, P. S., & Agrawal, V. K. (2006). *Cell Biology, Genetics, Molecular Biology, Evolution & Ecology* (1 ed.). S.Chand and company Ltd.
- [4] Klug, W. S., & Cummings, M. R. (2003). *Concepts of genetics*. Upper Saddle River, N.J: Prentice Hall.
- [5] <https://byjus.com/biology/recombinant-dna-technology/>
- [6] https://en.wikipedia.org/wiki/Recombinant_DNA
- [7] <https://www.biologyexams4u.com/2015/04/enzymes-in-recombinant-dna-or-rdna.html#.XsoliOfhXIU>.
- [8] Kokare.C.R; *Pharmaceutical Biotechnology fundamental and application; NIRALI PRAKSHAN;PP-10.1-10.2*
- [9] P. T. Lomedico, "Use of recombinant DNA technology to program eukaryotic cells to synthesize rat proinsulin: a rapid expression assay for cloned genes," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 79, no.19, pp. 5798–5802, 1982
- [10] M. Cavazzana-Calvo, S. Hacein-Bey, G. De Saint Basile et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," *Science*, vol. 288, no. 5466, pp. 669–672 2000.
- [11] S. Hacein-Bey-Abina, F. Le Deist, F. Carlier et al., "Sustained correction of X-linked severe combined immunodeficiency *bex vivo* gene therapy," *The New England Journal of Medicine*, vol.346, no. 16, pp. 1185–1193, 2002.
- [12] M. G. Ott, M. Schmidt, K. Schwarzwaelder et al., "Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EV11, PRDM1 or SETBP1," *Nature Medicine*, vol. 12, no. 4, pp. 401–409, 2006.
- [13] Stein, M. G. Ott, S. Schultze-Strasser et al., "Genomic instability and myelodysplasia with monosomy 7 consequent to EV11 activation after gene therapy for chronic granulomatous

REFERENCES

- disease,” *Nature Medicine*, vol. 16, no. 2, pp. 198–204, 2010.
- [14] A. Rostami-Hodjegan and G. T. Tucker, “Simulation and prediction of in vivo drug metabolism in human populations from in vitro data,” *Nature Reviews Drug Discovery*, vol. 6, no. 2, pp. 140–148, 2007.
- [15] J. K. Nicholson, E. Holmes, and I. D. Wilson, “Gut microorganisms, mammalian metabolism and personalized health care,” *Nature Reviews Microbiology*, vol. 3, no. 5, pp. 431–438, 2005.
- [16] S. Ripp, D. E. Nivens, Y. Ahn et al., “Controlled field release of a bioluminescent genetically engineered microorganism for bioremediation process monitoring and control,” *Environmental Science and Technology*, vol. 34, no. 5, pp. 846–853, 2000.
- [17] G. S. Saylor, C. D. Cox, R. Burlage et al., “Field application of a genetically engineered microorganism for polycyclic aromatic hydrocarbon bioremediation process monitoring and control,” in *Novel Approaches for Bioremediation of Organic Pollution*, pp 241–254, Springer, New York, NY, USA, 1999.
- [18] Paoletti MG, Pimentel D. Genetic [APP] engineering in agriculture and the environment—assessing risks and benefits. *BioScience*. 1996; 46(9):665–673.
- [19] Bruening G, Lyons JM. The case of the FLAVR SAVR tomato. *California Agriculture*. 2000; 54(4):6–7.
- [20] Winerip M. You call that a tomato? *The New York Times*, USA; 2003.